Internal Medicine, Infectious Disease · Visalia, CA
NPI
1538250808
Since 2006
Specialty
Internal Medicine, Infectious Disease
Code 207RI0200X
Group practices
5
Medicare group memberships
Hospitals
2
Hospital affiliations
116 N Akers St
Visalia, CA, 93291
Phone (559) 624-2735
Groups this clinician bills Medicare through
Medicare paid, 2024
$55K
814 services
Medicare patients, 2024
281
Average age 72
Drug cost, 2024
$1.8M
831 prescriptions
Company payments, 2025
$24.74
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Daniel J Boken was code 99231 (hospital e&m - subsequent), 270 times for 148 patients. In total Daniel J Boken billed 814 services in 11 codes, and Medicare paid $55K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2007-12-10.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99231 Hospital E&M - Subsequent | Facility | 270 | 148 | $38.28 | $10K |
| 99222 Hospital E&M - Initial | Facility | 229 | 220 | $100.82 | $23K |
| 99232 Hospital E&M - Subsequent | Facility | 206 | 115 | $61.56 | $13K |
| 99233 Hospital E&M - Subsequent | Facility | 35 | 29 | $90.53 | $3,169 |
| 99213 Office E&M - Established | Office | 34 | 24 | $63.05 | $2,144 |
| 99203 Office E&M - New | Office | 12 | 12 | $82.04 | $984 |
By year: 2022 $73K for 1,083 services; 2023 $58K for 826 services; 2024 $55K for 814 services.
Medicare prescription drug claims, 2024
In 2024, the drug Daniel J Boken prescribed most often to Medicare patients was Fluconazole, with 142 prescriptions and refills. In total Daniel J Boken wrote 831 Medicare prescriptions that cost $1.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Fluconazole Generic | 142 | 163 | 29 | $12K |
| Dovato Dolutegravir Sodium/Lamivudine | 130 | 136 | 17 | $392K |
| Triumeq Abacavir/Dolutegravir/Lamivudi | 76 | 78 | Under 11 | $279K |
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | 71 | 77 | 12 | $300K |
| Efavirenz-Emtric-Tenofov Disop Efavirenz/Emtricit/Tenofovr Df | 68 | 76 | Under 11 | $44K |
| Tivicay Dolutegravir Sodium | 42 | 42 | Under 11 | $96K |
| Juluca Dolutegravir/Rilpivirine | 29 | 29 | Under 11 | $100K |
| Ritonavir Generic | 24 | 26 | Under 11 | $3,085 |
| Emtricitabine-Tenofovir Disop Emtricitabine/Tenofovir (Tdf) | 24 | 24 | Under 11 | $1,560 |
| Odefsey Emtricitab/Rilpiviri/Tenof Ala | 23 | 23 | Under 11 | $78K |
| Descovy Emtricitabine/Tenofov Alafenam | 22 | 30 | Under 11 | $66K |
| Isentress Raltegravir Potassium | 19 | 27 | Under 11 | $52K |
| Genvoya Elviteg/Cob/Emtri/Tenof Alafen | 18 | 20 | Under 11 | $79K |
| Complera Emtricita/Rilpivirine/Tenof Df | 14 | 14 | Under 11 | $50K |
| Atazanavir Sulfate Generic | 14 | 18 | Under 11 | $7,048 |
Brand drugs: 470 claims; generic drugs: 361 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Daniel J Boken $24.74 ($24.74 in general payments such as food, travel and fees) from 1 company. The largest payer was Gilead Sciences, Inc. with $24.74.
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. GILD | 1 | $24.74 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.